WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has filed a national phase patent application with the Indian patent office for its innovative heart failure treatment, Istaroxime. The application, entitled “ISTAROXIME AND DERIVATIVES THEREOF FOR PREVENTING OR REDUCING THE RISK OF ACUTE MYOCARDIAL ARRHYTHMIA,” underlines the company’s ongoing efforts to address serious cardiac conditions globally.
Arrhythmias, irregular heart rhythms that impair the heart’s ability to pump blood effectively, can be life-threatening for individuals with heart failure or cardiomyopathy. Existing treatments, including catecholamines, often exacerbate the risk of arrhythmias, creating a critical need for therapies that not only improve heart function but also reduce such risks.
Strategic Focus on Emerging Markets
India, with a population exceeding 1.4 billion, represents a significant avenue for Windtree’s intellectual property strategy as it advances Istaroxime toward Phase 3 readiness in cardiogenic shock. “India’s population is greater than 1.4 billion people making it a part of our Istaroxime strategic intellectual property plan,” said Jed Latkin, CEO of Windtree Therapeutics. “As we prepare for Phase 3 readiness in cardiogenic shock, we plan to obtain intellectual property protection in key markets such as India.”
Istaroxime’s Dual-Mechanism Advantage
Istaroxime stands out as a first-in-class therapy with a dual mechanism specifically designed to improve both systolic and diastolic cardiac function. It operates as a positive inotropic agent, enhancing myocardial contractility by inhibiting Na+/K+-ATPase. Simultaneously, it promotes myocardial relaxation by activating the SERCA2a calcium pump, which enhances calcium reuptake from the cytoplasm. This refined mechanism has been demonstrated in multiple Phase 2 studies to improve cardiac function, stabilize blood pressure, and reduce arrhythmia risk—all without increasing heart rate.
By refining both contraction and relaxation phases of the heart’s pumping cycle, istaroxime addresses critical shortcomings of existing therapies, offering a promising alternative for patients with acute decompensated heart failure and early cardiogenic shock.
With patent protections expanding into pivotal international markets like India, Windtree Therapeutics is strategically positioning itself to deliver innovative, life-saving therapies to regions with significant unmet medical needs. Istaroxime’s potential marks a significant step forward in arrhythmia and heart failure treatment on a global scale.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.